Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322854 | 0.95 | PPARA (0.44) | PPARATMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL6319175 | 0.95 | PPARA (0.44) | PPARATMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL6322860 | 0.95 | PPARA (0.44) | PPARATMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL6319181 | 0.95 | PPARA (0.44) | PPARATMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL6316341 | 0.93 | PPARA (0.43) | PPARATMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL6316343 | 0.93 | PPARA (0.43) | PPARATMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL6322934 | 0.93 | PPARA (0.43) | PPARATMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL6322942 | 0.93 | PPARA (0.43) | PPARATMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL6320755 | 0.91 | PTGES (0.42) | PPARATMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL6318185 | 0.91 | HSP90AA1 (0.43) | PPARATMEM97SIGMAR1ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | claimed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | claimed |
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | disclosed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | HAVCR2, ZC3HAV1, MAVS | PPARA 2311/4885TMEM97 2467/4885SIGMAR1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.